ARCT$7.61
$7.72
Chart
Performance
Key Stats
AI ARCT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldArcturus Therapeutics Holdings Inc. shows strong potential in its therapeutic pipeline, but faces significant near-term financial performance challenges and a volatile technical outlook. A balanced approach is recommended.
Thematic
Arcturus Therapeutics is positioned in the high-growth biotechnology sector, focusing on rare diseases and infectious diseases, which are areas with significant unmet needs and potential for innovation.
Fundamental
The company has a strong cash position but is currently unprofitable with negative earnings and cash flow. Recent revenue trends have been mixed.
Technical
The stock is experiencing high volatility and is trading below its longer-term moving averages, suggesting short-term weakness. However, some oscillators indicate potential for a bounce.
| Factor | Score |
|---|---|
| Rare Disease Therapies | 85 |
| Infectious Disease Vaccines | 70 |
| mRNA Technology Advancement | 80 |
| Biotech Market Trends | 60 |
| Competition | 55 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 25 |
| Balance Sheet Health | 70 |
| Cash Flow | 15 |
| Debt Level | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 50 |
| Short-term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive Earnings Surprise Trend
Over the last several quarters, Arcturus Therapeutics Holdings Inc. (ARCT) has demonstrated a trend of beating earnings per share (EPS) estimates. For instance, in Q2 2024, the reported EPS of -0.52 significantly beat the estimate of -1.33, with a surprise of 60.93%. This consistent outperformance suggests effective operational management and potentially underestimated future earnings power.
Improving Revenue and Net Margin Trends
While net margins have been negative, there are signs of improvement. For example, the net margin in Q4 2023 was -18.8%, which improved from -1648.0% in Q4 2021. Coupled with revenue growth (e.g., from $12.36M in Q4 2021 to $157.75M in Q4 2023), this indicates a potential turnaround and a step towards profitability.
Bearish Points (6)
Negative Earnings and High Price-to-Sales
The company consistently reports negative Earnings Per Share (EPS) on a trailing twelve months (TTM) basis (-$2.52). Furthermore, the Price-to-Sales (P/S) ratio is high at 4.7 (TTM), indicating that the market valuation is significantly higher than its current revenue generation, which could be a risk if sales do not materialize as expected.
Consistent Net Losses
Arcturus Therapeutics Holdings Inc. has consistently reported net losses in recent years. For example, in 2024, the net income was a loss of $80.94 million. This persistent unprofitability, with negative net margins across all reported periods, highlights significant operational and financial challenges.
Calendar
November 2017
16
Next Dividend Date
August 2025
12
Next Earnings Date
H: $-0.34
A: $-0.87
L: $-1.76
H: 29.70M
A: 18.71M
0Profile
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Seasonals
Price Target
67.40 USD
The 39 analysts offering 1 year price forecasts for ARCT have a max estimate of 140.00 and a min estimate of 35.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct and major competitor in mRNA vaccine and therapeutic development, pioneering the field alongside BioNTech.
Weight: 98
Direct and major competitor in mRNA vaccine and therapeutic development, famous for its partnership with Pfizer on COVID-19 vaccines.
Weight: 95
Direct pure-play mRNA company, a key competitor in the development of mRNA-based vaccines and therapies.
Weight: 92
Major pharmaceutical company that has heavily invested in mRNA technology through its partnership with BioNTech, a dominant player in the vaccine market.